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impetus to definitely conclude that an
increase and subsequent decrease of GM
after administration of caspofungin rep-
resents treatment failure. In our patient,
this was not the case. An increase and de-
crease in GM during therapy does not nec-
essarily presage the outcome in one way
or another. Our point was that one should
exercise caution in interpreting the GM
serum ratio in patients who receive cas-
pofungin—or any other antifungal, for
that matter.
Acknowledgments
Potential conflicts of interest. P.E.V. has been
a consultant for Merck & Company, Gilead Sci-
ences, Schering-Plough, Pfizer, and Vicuron.
R.R.K. and J.P.D.: no conflicts.
Rocus R. Klont,1,3 J. Peter Donnelly,2,3
and Paul E. Verweij1,3
Departments of 1Medical Microbiology
and 2Hematology, Radboud University Nijmegen
Medical Center, and 3Nijmegen University Center
for Infectious Diseases, Nijmegen, The Netherlands
References
1. Miceli MH, Anaissie EJ. When a paradoxical
increase in serum galactomannan antigen dur-
ing caspofungin therapy is not paradoxical after
all. Clin Infect Dis 2007; 44:757–60.
2. Klont RR, Mennink-Kersten MA, Ruegebrink
D, et al. Paradoxical increase in circulating As-
pergillus antigen during treatment with cas-
pofungin in a patient with pulmonary asper-
gillosis. Clin Infect Dis 2006; 43:e23–5.
3. Maertens J, Glasmacher A, Selleslag D, et al.
Evaluation of serum sandwich enzyme-linked
immunosorbent assay for circulating galacto-
mannan during caspofungin therapy: results
from the caspofungin invasive aspergillosis
study. Clin Infect Dis 2005; 41:e9–14.
4. Petraitis V, Petraitiene R, Sarafandi AA, et al.
Combination therapy in treatment of experi-
mental pulmonary aspergillosis: synergistic in-
teraction between an antifungal triazole and an
echinocandin. J Infect Dis 2003; 187:1834–43.
5. Verweij PE, Weemaes CM, Curfs JH, Bretagne
S, Meis JF. Failure to detect circulating Asper-
gillus markers in a patient with chronic gran-
ulomatous disease and invasive aspergillosis. J
Clin Microbiol 2000; 38:3900–1.
6. van Vianen W, de Marie S, ten Kate MT, Mathot
RA, Bakker-Woudenberg IA. Caspofungin: an-
tifungal activity in vitro, pharmacokinetics, and
effects on fungal load and animal survival in
neutropenic rats with invasive pulmonary as-
pergillosis. J Antimicrob Chemother 2006; 57:
732–40.
7. Wiederhold NP, Kontoyiannis DP, Jingduan C,
et al. Pharmacodynamics of caspofungin in a
murine model of invasive pulmonary aspergil-
losis: evidence of concentration-dependent ac-
tivity. J Infect Dis 2004; 190:1464–71.
8. Scotter JM, Chambers ST. Comparison of gal-
actomannan detection, PCR-enzyme-linked
immunosorbent assay, and real-time PCR for
diagnosis of invasive aspergillosis in a neutro-
penic rat model and effect of caspofungin ac-
etate. Clin Diagn Lab Immunol 2005; 12:
1322–7.
Reprints or correspondence: Dr. Rocus R. Klont, Dept. of Med-
ical Microbiology, Radboud University Nijmegen Medical Cen-
ter, Nijmegen University Center for Infectious Diseases, P.O.
Box 9101, 6500 HB Nijmegen, The Netherlands (r.klont@
mmb.umcn.nl).
Clinical Infectious Diseases 2007; 44:760–1
 2007 by the Infectious Diseases Society of America. All
rights reserved. 1058-4838/2007/4405-0024$15.00
Illness in Travelers Visiting
Friends and Relatives: What
Can Be Concluded?
To the Editor—We were interested to
read the GeoSentinel report by Leder et
al. [1] that focused on an important group
of international travelers who, to date,
have not been clearly defined in terms of
demographic characteristics and travel-
related morbidity. We suggest that there
are significant issues related to the design,
analysis, interpretation, and conclusions
of the study that require comment. Al-
though Leder and colleagues acknowledge
several limitations in their report, practi-
tioners who are not familiar with the na-
ture of the GeoSentinel program and/or
who do not work with migrant travelers
may not fully appreciate the significance
of these limitations.
First, although the classification of trav-
elers into 3 groups looks appealing, the
classifications have been applied retroac-
tively to the data, and the consequences
of this are significant. The retrospective
cohort nature of the study design limits
the interpretation of outcomes to a cohort
association and diminishes the generaliz-
ability of the conclusions to wider practice
outside of the participating GeoSentinel
centers.
Second, there is no design evidence that
the recategorization of travelers into “im-
migrant visiting friends and relatives,”
“traveler visiting friends and relatives,”
and “tourist,” as defined within the report,
is either robust or reliably discriminating
for travel-related risk or for health out-
comes.
Third, the data recruitment allows for
the introduction of both patient referral
and selection bias. This may create epi-
demiological associations that may not be
representative of travelers outside of the
study group. GeoSentinel sites are often
academic or tertiary care centers, and are
predominantly based in America; thus,
they may be biased towards recruiting
tourists rather than travelers visiting
friends and relatives. Patterns of access to
medical service by migrants may differ
from those of the host population [2]. Al-
lowable health insurance coverage and is-
sues of willingness to pay for services in
the visited nation [3] may influence pre-
travel and posttravel service use by trav-
elers visiting friends and relatives. Insur-
ance coverage may be linked to the study’s
observations of early clinical presentation
by tourist travelers, compared with the
travelers visiting friends and relatives (who
have limited insurance) .
Other design considerations include the
acquisition of diseases, such as malaria,
which are primarily related to the desti-
nation rather than the reason for travel.
Analysis of travel to regions of West Africa
and East and southern Africa would have
been more reflective of actual risk than
reasons for travel. There is evidence that
travelers visiting friends and relatives are
overrepresented as travelers [4] to both
Asia and sub-Saharan Africa, and the rel-
ative high proportion of disease prevalence
in the group may be a reflection of greater
exposure to and not increased likelihood
of disease. The differing pattern of mor-
bidity among the groups of travelers and
immigrants visiting friends and relatives
may relate to their economic status, access
to and use of services, and medical care–
seeking behavior, rather than to travel-
associated risk.
All of these factors combined are design
issues that we believe makes studies like
the Leder et al. [1] study difficult to extend
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beyond the participating GeoSentinel clin-
ics. Nonetheless, the report by Leder and
colleagues and similar studies highlight the
importance of defining and determining
population-based risk factors in cohorts
of travelers. Existing limitations of current
data at this time do not allow the asso-
ciations of outcomes that are demon-
strated in the report to be extended to all
travelers and immigrants visiting friends
and relatives or migrant travelers.
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Reply to Behrens et al.
To the Editor—We appreciate the op-
portunity to discuss several points ad-
dressed by Behrens et al. [1], some of
which were already addressed in our orig-
inal article [2]. GeoSentinel is a network
of 33 globally dispersed clinics, mostly at
academic or tertiary care centers. We have
acknowledged the possibility of referral or
selection biases that may limit generaliz-
ability of our findings beyond specialized
travel and/or tropical medicine clinics.
GeoSentinel data are not predomi-
nantly from the US population. Of the
60,000 patients in the entire database, 42%
were seen at clinic sites in Asia, 26% in
Europe, 20% in the United States, 9% in
Canada, and 3% in Australia and New
Zealand. For our study [2], 44% of the
immigrants visiting friends and relatives
were seen at clinic sites in Europe, 30%
in Canada, 21% in the United States, and
5% in Australia and New Zealand.
GeoSentinel clinics serve diverse patient
populations; some clinics see greater pro-
portions of immigrants, and others see
more travelers. At the average US Geo-
Sentinel site, 25% of the patients are im-
migrants visiting friends and relatives.
Eleven percent of patients at European
sites and 23% of patients at Canadian sites
are immigrants visiting friends and
relatives.
The categorization of travelers as “vis-
iting friends and relatives” in itself implies
a number of differences, including pre-
vious exposure, genetic predisposition,
types of exposure during travel, and med-
ical care–seeking patterns. We agree with
Behrens et al. [1] that, in most countries,
access to and use of medical services may
differ between groups of travelers visiting
friends and relatives and other travelers.
The different patterns of morbidity among
the groups of travelers visiting friends and
relatives may relate not only to their travel-
associated risk, but also to behavioral, cul-
tural, and economic factors.
As noted by Behrens et al. [1], certain
diagnoses primarily relate to the region
visited, and travelers visiting friends and
relatives are overrepresented as travelers to
some regions. To correct for this, we pre-
sented results by region (tables 2–4), with
logistic regressions to adjust for destina-
tion and other possible confounders (fig-
ure 1) [2]. Insufficient data precluded sep-
aration of West from East and southern
Africa. As stated in the article, our results
do not indicate the rate of incidence of
disease or absolute risk of disease, but
rather reflect relative morbidity.
Because travelers visiting friends and
relatives generally do not seek medical care
prior to travel [3], prospective studies do
not exist. In our study [2], patient data
were collected in a standardized way, with
predesignated data fields; thus, the retro-
active classification into 3 groups is irrel-
evant. As stated, some misclassification of
immigrants visiting friends and relatives
and travelers visiting friends and relatives
may have occurred. However, by catego-
rizing travelers and immigrants visiting
friends and relatives into subgroups, we
have shown significant differences be-
tween groups in the relative morbidity for
a number of travel related diseases. As with
any original approach to an issue, we have
not claimed that the groups are robust;
our results require validation to determine
whether they can be replicated.
A recent exhaustive literature review
concluded that “there are no published
recommendations and little data on pro-
viding care to this population of travelers”
[4, p. 2857]. Other recent authoritative re-
views have found few primary studies of
this population [5, 6]. Our results repre-
sent, to our knowledge, the first data fo-
cused solely on populations of travelers
and immigrants visiting friends and rela-
tives from a global surveillance network
and clearly highlight significant issues of
morbidity among this population, com-
pared with tourist travelers. Our findings
suggest important considerations for ad-
ditional understanding of migrant pop-
ulations.
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